Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz with Stavudine and Lamivudine in ART-Naive HIV
NCT00002227Phase 2Completed
- Sponsor
- Merck & Co.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efavirenz in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Reduction in Plasma HIV-1 RNA at 24 weeks and Proportion of patients with HIV-1 RNA < 50 copies/mL at 24 weeks. Status: completed.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002227.